A new immuno-oncology target – SUMOylation
Trends in Cancer · 2023-08 · 9 (8) · 606-608
DOI: 10.1016/j.trecan.2023.04.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Cancer, 2023-08. Verfasst von Yuan Chen. Beteiligte Einrichtung: Division of Surgical Sciences, Department of Surgery, UC San Diego Health, La Jolla, CA 92037, USA; Moores Cancer Center, UC San Diego Health, La Jol…. Hauptthemen laut MEDLINE: Sumoylation, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Pancreatic Cancer Action Network, National Institutes of Health.
Abstract (Originalsprache)
Immunotherapy has been a paradigm shift in cancer treatment to produce durable responses. Unfortunately, most cancers do not respond to current immunotherapies, and thus, exploring novel mechanisms is crucial. Emerging data now demonstrate that protein modification by the small ubiquitin-like modifiers (SUMO) is a novel target to activate antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Surgical Sciences, Department of Surgery, UC San Diego Health, La Jolla, CA 92037, USA; Moores Cancer Center, UC San Diego Health, La Jolla, CA 92037, USA. Electronic address: Yuc020@health.ucsd.edu.
Förderung
- NCI NIH HHS
- Pancreatic Cancer Action Network
- National Institutes of Health
Zitieren
APA
Chen, Y. (2023). A new immuno-oncology target – SUMOylation. Trends in Cancer, 9(8), 606-608. https://doi.org/10.1016/j.trecan.2023.04.010
Vancouver
Chen Y. A new immuno-oncology target – SUMOylation. Trends in Cancer. 2023;9(8):606-608. doi:10.1016/j.trecan.2023.04.010
BibTeX
@article{Chen2023,
author = {Chen, Yuan},
title = {A new immuno-oncology target – SUMOylation},
journal = {Trends in Cancer},
year = {2023},
volume = {9},
number = {8},
pages = {606--608},
doi = {10.1016/j.trecan.2023.04.010}
}
EUVIMED